NEXI Stock Price, NexImmune, Inc. Quote, Chart

Market Summary

USD3.12-0.06

Market Closed

-1.89%

NEXI Stock Price

View Fullscreen

NEXI RSI Chart

NEXI Valuation

Market Cap

4.3M

Price/Earnings (Trailing)

-0.13

Price/Free Cashflow

-0.14

NEXI Price/Earnings (Trailing)

NEXI Profitability

Return on Equity

-921.57%

Return on Assets

-376.36%

Free Cashflow Yield

-735.89%

NEXI Fundamentals

NEXI Earnings

Earnings (TTM)

-32.3M

Earnings Growth (Yr)

68.28%

Earnings Growth (Qtr)

45.62%

Breaking Down NEXI Revenue

Last 7 days

-8.5%

Last 30 days

-41.8%

Last 90 days

-75.2%

Trailing 12 Months

906.5%

How does NEXI drawdown profile look like?

NEXI Financial Health

Current Ratio

1.06

NEXI Investor Care

Buy Backs (1Y)

94.74%

Diluted EPS (TTM)

-22.94

Tracking the Latest Insider Buys and Sells of NexImmune, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 22, 2023	roemer alan s.	sold	-7,758	1.9434	-3,992	-
Nov 21, 2023	roemer alan s.	sold	-8,287	2.1621	-3,833	-
Mar 30, 2023	barer sol j	bought	164,120	0.4103	400,000	-
Nov 26, 2022	jones kristi	acquired	-	-	296,700	president and ceo
Nov 22, 2022	oelke mathias	acquired	-	-	126,100	chief science officer
Nov 22, 2022	trainer john	acquired	-	-	125,200	chief financial officer
Nov 17, 2022	barer sol j	bought	35,917	0.4789	75,000	-
Nov 16, 2022	barer sol j	bought	60,300	0.4824	125,000	-
Jun 07, 2022	verstandig grant	bought	61,384	2.284	26,876	-
Jun 06, 2022	verstandig grant	bought	53,537	2.1415	25,000	-

Which funds bought or sold NEXI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	BNP PARIBAS FINANCIAL MARKETS	new	-	230	230	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	new	-	60,610	60,610	-%
Mar 22, 2024	PNC Financial Services Group, Inc.	sold off	-100	-66,368	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	new	-	28,061	28,061	-%
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-20,427	-	-%
Feb 14, 2024	Royal Bank of Canada	sold off	-100	-	-	-%
Feb 14, 2024	Royal Bank of Canada	new	-	2,000	2,000	-%
Feb 14, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	sold off	-100	-10,000	-	-%

Are Funds Buying or Selling NEXI?

Are funds buying NEXI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NEXI

No. of Funds

Unveiling NexImmune, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 07, 2023	barer sol j	9.17%	2,392,826	SC 13D
Feb 15, 2023	arrowmark colorado holdings llc	0.04%	10,924	SC 13G/A
Feb 13, 2023	artal international s.c.a.	4.6%	1,200,000	SC 13G/A
Feb 13, 2023	barer sol j	7.6%	1,992,826	SC 13G/A
Feb 13, 2023	b&s neximmune holdco llc	5.9%	1,538,013	SC 13G/A
Feb 22, 2022	brady louise f.	6.88%	1,563,124	SC 13G
Feb 18, 2022	long robert e. jr.	6.65%	1,510,664	SC 13G
Feb 14, 2022	piedmont capital partners, llc	6.08%	1,381,938	SC 13G
Feb 14, 2022	arrowmark colorado holdings llc	7.94%	1,803,232	SC 13G/A
Feb 11, 2022	b&s neximmune holdco llc	6.8%	1,538,013	SC 13G

Recent SEC filings of NexImmune, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 16, 2024	10-K	Annual Report
Apr 10, 2024	3	Insider Trading
Apr 05, 2024	8-K	Current Report
Mar 29, 2024	NT 10-K	NT 10-K
Feb 06, 2024	DEFA14A	DEFA14A
Feb 05, 2024	8-K	Current Report
Feb 05, 2024	424B5	Prospectus Filed
Feb 02, 2024	8-K	Current Report
Feb 01, 2024	8-K	Current Report

Peers (Alternatives to NexImmune, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

NexImmune, Inc. News

Latest updates

NexImmune, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-41.0%	9.00	15.00	23.00	31.00	43.00	58.00	66.00	78.00	91.00	105	115	127	11.00
Current Assets	-47.7%	5.00	10.00	19.00	25.00	37.00	52.00	60.00	72.00	86.00	99.00	111	123	8.00
Cash Equivalents	-64.2%	3.00	9.00	16.00	22.00	35.00	46.00	41.00	25.00	30.00	37.00	64.00	118	5.00
Net PPE	-63.5%	1.00	4.00	4.00	4.00	4.00	5.00	5.00	4.00	4.00	4.00	4.00	4.00	3.00
Liabilities	-19.4%	5.00	6.00	6.00	7.00	11.00	10.00	10.00	8.00	7.00	7.00	5.00	6.00	27.00
Current Liabilities	-18.1%	5.00	6.00	6.00	7.00	10.00	9.00	9.00	7.00	7.00	7.00	5.00	6.00	27.00
Shareholder's Equity	-57.5%	4.00	8.00	17.00	24.00	32.00	48.00	56.00	70.00	84.00	97.00	110	120	-
Retained Earnings	-2.5%	-222	-217	-207	-199	-190	-173	-158	-142	-127	-112	-97.57	-85.39	-77.58
Additional Paid-In Capital	0.3%	226	225	224	223	223	221	214	213	211	209	207	206	8.00
Shares Outstanding	-	1.00	-	26.00	26.00	-	-	23.00	23.00	23.00	23.00	23.00	13.00	1.00
Float	-	-	-	6.00	-	-	-	29.00	-	-	-	298	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	19.9%	-5,832	-7,284	-6,029	-12,284	-11,124	-11,866	-11,724	-16,475	-11,438	-9,577	-13,614	-11,155	-7,191	-6,695	-6,007	-6,510
Share Based Compensation	-44.5%	614	1,106	991	842	1,478	1,437	1,309	1,646	1,670	1,628	1,483	1,197	274	284	340	319
Cashflow From Investing	-100.0%	-	3.00	-5.02	-42.72	-143	11,937	27,902	10,619	4,004	-17,195	-40,034	-580	-226	-248	-61.39	758
Cashflow From Financing	-	-	-	-	-	-	5,145	-	33.00	504	213	-637	124,808	10,469	4,334	7,287	-4.83

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

NEXI Income Statement

2023-12-31

Statements Of Operations - USD ($)	12 Months Ended
Statements Of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 19,282,230	$ 47,148,450
General and administrative	13,000,624	15,934,439
Loss on assets held for sale	690,768	0
Total operating expenses	32,973,622	63,082,889
Loss from operations	(32,973,622)	(63,082,889)
Other income (expense), net:
Interest income	698,395	664,372
Other expense	(69,166)	(87,682)
Total other income, net	629,229	576,690
Net loss	(32,344,393)	(62,506,199)
Net loss available to common stockholders’	$ (32,344,393)	$ (62,506,199)
Basic net loss attributable to common stockholders per common share (in dollars per share)	$ (30.82)	$ (64.95)
Diluted net loss attributable to common stockholders per common share (in dollars per share)	$ (30.82)	$ (64.95)
Basic weighted average number of common shares outstanding (in shares)	1,049,468	962,364
Diluted weighted-average number of common shares outstanding (in shares)	1,049,468	962,364

NEXI Balance Sheet

2023-12-31

Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 3,202,452	$ 34,642,340
Restricted cash	20,000	55,000
Assets held for sale	1,444,043	0
Prepaid expenses and other current assets	734,464	2,671,411
Total current assets	5,400,959	37,368,751
Property and equipment, net	1,352,901	4,459,071
Operating lease right-of-use assets, net	46,716	967,032
Other non-current assets	1,793,373	264,970
Total assets	8,593,949	43,059,824
Current liabilities:
Accounts payable	1,336,318	2,377,374
Accrued expenses and other current liabilities	3,679,105	7,357,153
Operating lease liabilities, current	68,809	599,047
Total current liabilities	5,084,232	10,333,574
Operating lease liabilities, non-current	0	425,766
Total liabilities	5,084,232	10,759,340
Commitments and contingencies
Stockholders’ equity
Common Stock, $0.0001 par value, 250,000,000 shares authorized as of December 31, 2023 and 2022, 1,066,320 and 1,043,138 issued and outstanding as of December 31, 2023 and 2022	2,646	2,608
Additional paid-in-capital	226,101,118	222,547,530
Accumulated deficit	(222,594,047)	(190,249,654)
Total stockholders’ equity	3,509,717	32,300,484
Total liabilities and stockholders’ equity	$ 8,593,949	$ 43,059,824

About NexImmune, Inc.

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. The company was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

CEO	Ms. Kristi Jones R.Ph.
WEBSITE	neximmune.com
INDUSTRY	Biotechnology
EMPLOYEES	50

NexImmune, Inc. Frequently Asked Questions

What is the ticker symbol for NexImmune, Inc.? What does NEXI stand for in stocks?

NEXI is the stock ticker symbol of NexImmune, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of NexImmune, Inc. (NEXI)?

As of Thu May 02 2024, market cap of NexImmune, Inc. is 4.28 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NEXI stock?

You can check NEXI's fair value in chart for subscribers.

What is the fair value of NEXI stock?

You can check NEXI's fair value in chart for subscribers. The fair value of NexImmune, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of NexImmune, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NEXI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is NexImmune, Inc. a good stock to buy?

The fair value guage provides a quick view whether NEXI is over valued or under valued. Whether NexImmune, Inc. is cheap or expensive depends on the assumptions which impact NexImmune, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NEXI.